These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23021375)

  • 1. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.
    Berg M; Soreide K
    Discov Med; 2012 Sep; 14(76):207-14. PubMed ID: 23021375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
    Baldus SE; Schaefer KL; Engers R; Hartleb D; Stoecklein NH; Gabbert HE
    Clin Cancer Res; 2010 Feb; 16(3):790-9. PubMed ID: 20103678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
    Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
    Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.
    Asghar U; Hawkes E; Cunningham D
    Clin Colorectal Cancer; 2010 Dec; 9(5):274-81. PubMed ID: 21208841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.
    Perkins G; Lièvre A; Ramacci C; Méatchi T; de Reynies A; Emile JF; Boige V; Tomasic G; Bachet JB; Bibeau F; Bouché O; Penault-Llorca F; Merlin JL; Laurent-Puig P
    Int J Cancer; 2010 Sep; 127(6):1321-31. PubMed ID: 20049837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
    Custodio A; Feliu J
    Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
    Sebio A; Paré L; Páez D; Salazar J; González A; Sala N; del Río E; Martín-Richard M; Tobeña M; Barnadas A; Baiget M
    Pharmacogenet Genomics; 2013 Mar; 23(3):142-7. PubMed ID: 23324806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer.
    Chua W; Moore MM; Charles KA; Clarke SJ
    Curr Opin Mol Ther; 2009 Dec; 11(6):611-22. PubMed ID: 20072938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy.
    Cejas P; López-Gómez M; Aguayo C; Madero R; Moreno-Rubio J; de Castro Carpeño J; Belda-Iniesta C; Barriuso J; Moreno García V; Díaz E; Burgos E; Gonzalez-Barón M; Feliu J
    Curr Cancer Drug Targets; 2012 Feb; 12(2):124-31. PubMed ID: 22229245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment.
    Dienstmann R; Tabernero J
    Cancer J; 2016; 22(3):149-55. PubMed ID: 27341591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.
    Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M
    Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Perspective of personalized (precise) cancer therapy based on predictive biomarkers].
    Osera S; Yoshino T
    Nihon Rinsho; 2014 Jan; 72(1):29-34. PubMed ID: 24597345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of apoptosis induction of thienopyrimidine compounds on KRAS and BRAF mutated colorectal cancer cell lines.
    Pédeboscq S; Gravier D; Casadebaig F; Hou G; Gissot A; Rey C; Ichas F; De Giorgi F; Lartigue L; Pometan JP
    Bioorg Med Chem; 2012 Nov; 20(22):6724-31. PubMed ID: 23063521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options.
    Scartozzi M; Bearzi I; Berardi R; Mandolesi A; Pierantoni C; Cascinu S
    Br J Cancer; 2007 Jul; 97(1):92-7. PubMed ID: 17579627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action.
    Heinemann V; Douillard JY; Ducreux M; Peeters M
    Cancer Treat Rev; 2013 Oct; 39(6):592-601. PubMed ID: 23375249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical biomarkers in oncology: focus on colorectal cancer.
    De Roock W; Biesmans B; De Schutter J; Tejpar S
    Mol Diagn Ther; 2009; 13(2):103-14. PubMed ID: 19537845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.
    Yang J; Li S; Wang B; Wu Y; Chen Z; Lv M; Lin Y; Yang J
    Tumour Biol; 2016 Sep; 37(9):11645-11655. PubMed ID: 27422777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Network quantification of EGFR signaling unveils potential for targeted combination therapy.
    Klinger B; Sieber A; Fritsche-Guenther R; Witzel F; Berry L; Schumacher D; Yan Y; Durek P; Merchant M; Schäfer R; Sers C; Blüthgen N
    Mol Syst Biol; 2013; 9():673. PubMed ID: 23752269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent therapeutic advances in the treatment of colorectal cancer.
    Ciombor KK; Wu C; Goldberg RM
    Annu Rev Med; 2015; 66():83-95. PubMed ID: 25341011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic-targeted therapy of thyroid cancer: a real promise.
    Xing M
    Thyroid; 2009 Aug; 19(8):805-9. PubMed ID: 19645612
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.